This new study, published yesterday, 3rd of October by the EuCARE partners from the Vilnius University Hospital Santaros Klinikos (VULSK), in the British Journal of Haematology, shows improved protection against Omicron infection and severe COVID-19 for those who received a third (booster) dose of mRNA vaccine.
In this study, the final cohort included 912 patients with haematological malignancies who had received the second BNT162b2 vaccine dose between 29 January and 1 September 2021, and had had no prior history of COVID-19 infection before January 1st 2022.
The study highlights that: “(…) the third BNT162b2 vaccine dose boosts antibody and T-cell immune responses and provides clinical protection against SARS-CoV-2 Omicron in a highly vulnerable haematological malignancy patients group”
Very importantly, the study “(…) identified a high-risk subgroup of patients with nearly absent anti-S1-IgG antibody response who should be offered enhanced protection against SARS-CoV-2 infection and may be candidates for a pre-emptive pharmacological intervention(…)”.
This study provides important evidence to guide SARS-CoV-2 vaccination schedules and therapy guidelines.
To read the full report go to: https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19126